Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
The Lancet Respiratory Medicine (2022) - Comments
pubmed: 36087611  doi: 10.1016/s2213-2600(22)00297-1  issn: 2213-2600  issn: 2213-2619 

Alexander P J Vlaar, Martin Witzenrath, Pieter Van Paassen, Leo M A Heunks, Bruno Mourvillier, Sanne De Bruin, Endry H T Lim, Matthijs C Brouwer, Pieter R Tuinman, José F K Saraiva, Gernot Marx, Suzana M Lobo, Rodrigo Boldo, Jesus A Simon-Campos, Alexander D Cornet, Anastasia Grebenyuk, Johannes M Engelbrecht, Murimisi Mukansi, Philippe G Jorens, Robert Zerbib